TOP > 外国特許検索 > CELLULAR-DISORDER INHIBITOR, MEDICINAL COMPOSITION CONTAINING SAID CELLULAR-DISORDER INHIBITOR FOR PREVENTION OR TREATMENT OF ORGAN DERANGEMENT CAUSED BY HYPOXEMIA, AND MEDICINAL COMPOSITION CONTAINING SAID CELLULAR-DISORDER INHIBITOR FOR PREVENTION OR TREATMENT OF ISCHEMIC CEREBROVASCULAR DISORDER

CELLULAR-DISORDER INHIBITOR, MEDICINAL COMPOSITION CONTAINING SAID CELLULAR-DISORDER INHIBITOR FOR PREVENTION OR TREATMENT OF ORGAN DERANGEMENT CAUSED BY HYPOXEMIA, AND MEDICINAL COMPOSITION CONTAINING SAID CELLULAR-DISORDER INHIBITOR FOR PREVENTION OR TREATMENT OF ISCHEMIC CEREBROVASCULAR DISORDER

外国特許コード F160008792
整理番号 (S2014-1592-N0,S2015-0263-N0)
掲載日 2016年8月4日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2015JP079023
国際公開番号 WO 2016060158
国際出願日 平成27年10月14日(2015.10.14)
国際公開日 平成28年4月21日(2016.4.21)
優先権データ
  • 特願2014-212064 (2014.10.16) JP
  • 特願2015-029698 (2015.2.18) JP
発明の名称 (英語) CELLULAR-DISORDER INHIBITOR, MEDICINAL COMPOSITION CONTAINING SAID CELLULAR-DISORDER INHIBITOR FOR PREVENTION OR TREATMENT OF ORGAN DERANGEMENT CAUSED BY HYPOXEMIA, AND MEDICINAL COMPOSITION CONTAINING SAID CELLULAR-DISORDER INHIBITOR FOR PREVENTION OR TREATMENT OF ISCHEMIC CEREBROVASCULAR DISORDER
発明の概要(英語) The present invention is a cellular-disorder inhibitor characterized by containing any one of peptides (a) to (g), a derivative thereof, or a salt or ester of these as an active ingredient.
特許請求の範囲(英語) [claim1]
1.  The following (a) ~ any peptide, a derivative thereof, or cytotoxic inhibitor characterized by containing these salts or esters as the active ingredient (g). (A) a peptide comprising the amino acid sequence shown in any of SEQ ID NO: 2, 5 to 10 and 17, (B) a peptide comprising the amino acid sequence shown in any of SEQ ID NO: 4, 11 ~ 16, 18, (C) in the amino acid sequence shown in any of SEQ ID NO: 2, 5 to 10 and 17, includes one or several amino acids are deleted, substituted or added in the amino acid sequence, and a peptide having cytotoxic ability to inhibit , (D) in the amino acid sequence shown in any of SEQ ID NO: 4, 11 - 16, 18, includes one or several amino acids are deleted, substituted or added in the amino acid sequence, and a peptide having cytotoxic ability to inhibit , (E) comprises an amino acid sequence amino acid sequence sharing an identity of 70% or more as shown in any of SEQ ID NO: 2, 5 to 10 and 17, and a peptide having cytotoxic inhibitory activity, (F) comprises an amino acid sequence amino acid sequence sharing an identity of 70% or more as shown in any of SEQ ID NO: 4, 11 ~ 16, 18, and a peptide having cytotoxic inhibitory activity, (G) (a) a fragment of any of ~ (f), and a peptide having cytotoxic suppression ability.
[2]
[claim2]
2.  The cytotoxicity-inhibitory ability is suppressed ability to cytotoxicity induced by hypoxic cytotoxic inhibitor of claim 1.
[3]
[claim3]
3.  Cytotoxic inhibitor according to claim 1 or 2, and pharmaceutically acceptable prophylactic or therapeutic pharmaceutical composition of organ damage caused by hypoxemia, characterized in that it comprises at least one of carriers and diluents object.
[4]
[claim4]
4.  Cytotoxic inhibitor according to claim 1, and pharmaceutically acceptable carrier and prophylactic or therapeutic pharmaceutical composition for ischemic cerebrovascular disorder characterized in that it comprises at least one of diluent.
[5]
[claim5]
5.  The content of the peptides in one administration, prophylactic or therapeutic pharmaceutical composition of ischemic cerebrovascular disorders as claimed in claim 4 is 1kg of body weight per 0.1mg or more.
[6]
[claim6]
6.  The content of the peptides in one administration, 1 kg prophylactic or therapeutic pharmaceutical composition of ischemic cerebrovascular disorders as claimed in claim 4 or less body weight per 0.4mg least 1 mg.
[7]
[claim7]
7.  After the onset of ischemic cerebrovascular disease, prevention or a pharmaceutical composition for the treatment of ischemic cerebrovascular disorders described in any one of claims 4-6, which is administered within 8 hours.
[8]
[claim8]
8.  After the onset of ischemic cerebrovascular disorder, prophylactic or therapeutic pharmaceutical composition of ischemic cerebrovascular disorders as claimed in any one of claims 4-7, which is administered within 7 hours.
[9]
[claim9]
9.  After the onset of ischemic cerebrovascular disorder, prophylactic or therapeutic pharmaceutical composition of ischemic cerebrovascular disorders as claimed in any one of claims 4 to 8 to be administered within 6 hours.
[10]
[claim10]
10.  Prophylactic or therapeutic pharmaceutical composition of ischemic cerebrovascular disorders as claimed in any one of claims 7-9, characterized in that it is used in combination with thrombolytic therapy.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NIHON UNIVERSITY
  • 発明者(英語)
  • HIDAI CHIAKI
  • MASUKO TAKASHI
  • KITANO HISATAKA
  • MAMIYA ATSUSHI
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
日本大学産官学連携知財センター(通称NUBIC,ニュービック)は,技術移転機関と知的財産本部の機能を兼ね備えた日本大学の産学連携の窓口です。
NUBICは,日本大学全教職員や大学院生・学部学生の豊富なアイデアや研究成果を,知的財産として戦略的に創出・保護・管理し,産業界のニーズとのマッチングを図り,企業の研究開発,新製品開発,新規事業の立上げが円滑に行われるようサポートいたします。
お気軽にご相談ください。

PAGE TOP

close
close
close
close
close
close